Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

BACKGROUND: Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qiaoping, Yuanyuan, Li, Jiejing, Zhu, Jian, Liu, Qingyu, Li, Lingya, Chen, Ying, Luo, Changchen, Shi, Yangling, Li, Wei, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901219/
https://www.ncbi.nlm.nih.gov/pubmed/33622356
http://dx.doi.org/10.1186/s12962-021-00264-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901219/
https://www.ncbi.nlm.nih.gov/pubmed/33622356
http://dx.doi.org/10.1186/s12962-021-00264-w

Ejemplares similares